Evidence map›Paper›PMID 36312000›Full record

ReviewWorld journal of diabetes2022

New therapeutic approaches for type 1 diabetes: Disease-modifying therapies.

Geza Nagy, Tekla Evelin Szekely, Aniko Somogyi, Magdolna Herold, Zoltan Herold

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Perceptions of the Benefits and Risks of Novel Therapies for Type 1 Diabetes: A Qualitative Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Prevention of Type 1 Diabetes in Children: A Worthy Challenge?International journal of environmental research and public health · 2023
    Review
  13. Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Geza NagyDepartment of Internal Medicine and Hematology, Semmelweis University, Budapest H-1088, Hungary. nagy.geza@med.semmelweis-univ.hu.
Tekla Evelin SzekelyDepartment of Internal Medicine and Hematology, Semmelweis University, Budapest H-1088, Hungary.
Aniko SomogyiDepartment of Internal Medicine and Hematology, Semmelweis University, Budapest H-1088, Hungary.
Magdolna HeroldDepartment of Internal Medicine and Hematology, Semmelweis University, Budapest H-1088, Hungary.
Zoltan HeroldDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest H-1083, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been 100 years since the first successful clinical use of insulin, yet it remains the only treatment option for type 1 diabetes mellitus (T1DM) patients. Advances in diabetes care, such as insulin analogue therapies and new devices, including continuous glucose monitoring with continuous subcutaneous insulin infusion have improved the quality of life of patients but have no impact on the pathogenesis of the disease. They do not eliminate long-term complications and require several lifestyle sacrifices. A more ideal future therapy for T1DM, instead of supplementing the insufficient hormone production (a consequence of β-cell destruction), would also aim to stop or slow down the destructive autoimmune process. The discovery of the autoimmune nature of type 1 diabetes mellitus has presented several targets by which disease progression may be altered. The goal of disease-modifying therapies is to target autoimmune mechanisms and prevent β-cell destruction. T1DM patients with better β-cell function have better glycemic control, reduced incidence of long-term complications and hypoglycemic episodes. Unfortunately, at the time symptomatic T1DM is diagnosed, most of the insulin secreting β cells are usually lost. Therefore, to maximize the salvageable β-cell mass by disease-modifying therapies, detecting autoimmune markers in an early, optimally presymptomatic phase of T1DM is of great importance. Disease-modifying therapies, such as immuno- and regenerative therapies are expected to take a relevant place in diabetology. The aim of this article was to provide a brief insight into the pathogenesis and course of T1DM and present the current state of disease-modifying therapeutic interventions that may impact future diabetes treatment.

Indexed as

Auto-immunityImmunotherapyIslet cellsMesenchymal stem cellRegenerative medicineType 1 diabetes

Identifiers

PMID36312000
PMCPMC9606789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.